Proteoheparan sulfate (PHS) proteoglycan (PG) on the endothelial cell surface and vascular basement membrane plays an important role in the vascular permeability barrier. Heparin sulfate (HS) contributes the majority of anionic charges to the vascular charge barrier. PHS protein core plays a structural role in the vascular barrier by its multiple binding sites for laminin, type IV collagen and other molecules. Animal models have demonstrated that cationic molecules which bind HS, and antibodies to PHS protein core, cause vascular injury. The investigators and others have demonstrated that sera from patients with autoimmune vascular disease have autoantibodies to PHS. The investigators hypothesis is that autoimmunity to PHS causes vascular injury in human autoimmune disease. The investigators propose that both humoral and cellular autoimmunity to PHS components (HS and protein core peptides) cause vascular injury by classic mechanisms, including the activation of complement, initiation of the inflammatory cascade, and endothelial cell cytotoxicity. The investigators also propose hypotheses regarding the immunochemistry of proteoglycan autoimmunity. First, while autoantibodies which broadly cross-react with anionic molecules have been described, the investigators have demonstrated autoantibodies to glycosaminoglycans (GAGS) which are highly specific. The investigators propose that these highly specific autoantibodies have high affinity for HS and are more efficient than broadly cross-reactive, low affinity autoantibodies in activating complement, and initiating inflammation. Thus, the investigators propose that antibody affinity determines the pathologic significance of autoimmunity to anionic molecules such as the GAGS. Secondly, PGs play a role in organ-specificity. The organ-specificity of proteoglycans is determined primarily by the nature of the protein core. The investigators propose that specific PHS protein core epitopes are immunologic targets in organ specific autoimmune disease. Finally, the investigators propose that cell-mediated immunity causes vascular injury via T-cell recognition of PHS sites which may differ from PHS epitopes recognized by autoantibody.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI024876-03
Application #
3138139
Study Section
Immunological Sciences Study Section (IMS)
Project Start
1990-01-01
Project End
1993-12-31
Budget Start
1992-01-01
Budget End
1993-12-31
Support Year
3
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Type
Schools of Medicine
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10029
Matic, M; Shibata, S; Fillit, H M (1997) Monoclonal antibody to heparan sulfate from autoimmune tight skin (TSK) mice binds to the endothelial cell surface. Immunol Invest 26:371-81
Fillit, H; Edstrom, W; Yang, C P et al. (1996) Autoimmune MRL mice express high-affinity IgG2b monoclonal autoantibodies to heparin. Clin Immunol Immunopathol 81:62-7
Dimitriu-Bona, A; Matic, M; Ding, W et al. (1995) Cytotoxicity to endothelial cells by sera from aged MRL/lpr/lpr mice is associated with autoimmunity to cell surface heparan sulfate. Clin Immunol Immunopathol 76:234-40
Shibata, S; Sasaki, T; Harpel, P et al. (1994) Autoantibodies to vascular heparan sulfate proteoglycan in systemic lupus erythematosus react with endothelial cells and inhibit the formation of thrombin-antithrombin III complexes. Clin Immunol Immunopathol 70:114-23
Shibata, S; Harpel, P C; Gharavi, A et al. (1994) Autoantibodies to heparin from patients with antiphospholipid antibody syndrome inhibit formation of antithrombin III-thrombin complexes. Blood 83:2532-40
Leveugle, B; Spik, G; Perl, D P et al. (1994) The iron-binding protein lactotransferrin is present in pathologic lesions in a variety of neurodegenerative disorders: a comparative immunohistochemical analysis. Brain Res 650:20-31
Leveugle, B; Scanameo, A; Ding, W et al. (1994) Binding of heparan sulfate glycosaminoglycan to beta-amyloid peptide: inhibition by potentially therapeutic polysulfated compounds. Neuroreport 5:1389-92
Shibata, S; Harpel, P; Bona, C et al. (1993) Monoclonal antibodies to heparan sulfate inhibit the formation of thrombin-antithrombin III complexes. Clin Immunol Immunopathol 67:264-72
Fillit, H; Shibata, S; Sasaki, T et al. (1993) Autoantibodies to the protein core of vascular basement membrane heparan sulfate proteoglycan in systemic lupus erythematosus. Autoimmunity 14:243-9
Dimitriu-Bona, A; Fillit, H (1993) Studies of the cellular immune response to heparan sulfate proteoglycan in the tight skin mouse. Cell Immunol 150:321-32

Showing the most recent 10 out of 12 publications